| Objective: To observe the effect of combine treatment of butorphanol combined with esketamine in patients with remifentanil induced hyperalgesia after laparoscopic gynecological surgery. Method:Based on randomized double-blind controlled trial,120 patients undergoing laparoscopic gynecological surgery in our hospital from April 2023 to October 2024 were divided into control group 1 (received esketamine treatment, n=40), control group 2 (received butorphanol treatment, n=40), and study group (received butorphanol combined with esketamine treatment, n=40). The awakening time, extubation time, mean arterial pressure (MAP), heart rate (HR), visual pain analog scale (VAS) score, ramsay sedation score, and incidence of adverse reactions among three groups were compared.Result:The awakening time and extubation time in the study group were shorter than those in the control group 1 and control group 2 (P<0.05). The MAP and HR in the study group were lower than those in the control group 1 and control group 2 at 30 minutes, 60 minutes after extubation (P<0.05). The VAS scores in the study group were lower than those in the control group 1 and control group 2 at 30 minutes, 60 minutes after extubation (P<0.05). The ramsay sedation scores in the study group were higher than those in the control group 1 and control group 2 at 30 minutes, 60 minutes after extubation (P<0.05). There was no significant difference in the incidence of postoperative adverse reactions among the three groups (P>0.05).Conclusion:Butorphanol combined with esketamine can further alleviate remifentanil induced hyperalgesia after laparoscopic gynecological surgery, exert good sedative and analgesic effects, maintain hemodynamic stability, and have good safety. |
